Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation
Seeking Alpha ·
Ironwood Pharmaceuticals ( IRWD ) announced on Wednesday that the Food and Drug Administration approved a label expansion for its AbbVie ( ABBV )-partnered bowel disorder therapy Linzess to treat children with functional constipation. Launched in 2022, Linzess was previously indicated in the U.S. to treat
AI 시장 분석
Ironwood and AbbVie's bowel disorder therapy, Linzess, has received U.S. FDA approval for a label expansion to treat functional constipation in children. This approval signifies an expanded market for Linzess and potential revenue growth for both pharmaceutical companies.
상승 영향
- Pharmaceuticals/Biotech — Linzess's label expansion for pediatric constipation broadens its market, directly boosting sales and revenue for Ironwood and AbbVie.
- Pediatric Medicine — A new treatment for pediatric functional constipation addresses unmet needs, fostering growth in the pediatric pharmaceutical market.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 29% · Bearish (Short) 71%
399 participants
Related News
- Taiwan breaks ground on advanced packaging park anchored by TSMC (2330 TT)
- BHP and China Baowu Extend Steel Decarbonisation Partnership
- Major Outages Hit Facebook and Instagram Across the United States
- What Drove XtalPi Stock Surge Today?
- Pre-Market Indian Equities Updates and Corporate Developments
- Asian Equities Rally Led by Tech Stocks Ahead of Trump-Xi Summit
